The effectiveness of vaccines is among the main data that determine whether the fight against coronavirus is close to a victory for science, and the data are increasingly encouraging, reports the Spanish agency EFE.
As CNN summarizes, two new different studies testify to the effectiveness of both Pfizer and AstraZeneca vaccines. The studies were conducted in Israel and the United Kingdom, respectively.
The Israeli study, conducted by the Clalit Research Institute, which is part of a large health system in the country, analyzed data on 1.2 million people, about half of whom received the Pfizer-BioNTech vaccine.
The incidence of symptomatic Covid-19, i.e. people who became infected with the coronavirus and felt unwell decreased by 94% among people who received two doses of the vaccine, according to Clalit. For its part, the percentage of serious diseases has dropped by 92%.
Examining a British study that was part of a monitoring project called AvonCAP funded by Pfizer, they found that a single dose of Pfizer-BioNTech or AstraZeneca injection was very effective in preventing symptomatic diseases severe enough to lead to hospitalization. patients over the age of 80 with many other diseases.
The Pfizer vaccine was 71.4% effective after 14 days in preventing hospitalization in patients with a mean age of 87 years, while one AstraZeneca vaccine was 80.4% effective according to the same measures in patients with a mean age of 88 years.
On the other hand, Reuters published preliminary data from a study conducted at the University of Oxford, which showed that the vaccine developed by AstraZeneca PLC is effective against P.1 or the Brazilian variant.
The data show that the vaccine does not need to be modified to protect against a strain believed to originate in the Amazon city of Manaus. The study has not yet been published.
On the other hand, early results indicate that the AstraZeneca vaccine is less effective against the South African variant, which is similar to P.1. Subsequently, South Africa stopped using the vaccine in the country.
Brazil is currently facing a brutal second wave of the coronavirus pandemic with a record 1,910 deaths on Wednesday. Option P.1 is among the factors that, according to epidemiologists, contribute to an increase in cases and deaths, and there is concern in the scientific community about the resistance of the option to vaccines.
– .
